1832 Asset Management
LCTX icon

1832 Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

1832 Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5
Closed -$5 – 938
2022
Q4 		$5 Hold
5
– – ﹤0.01% 885
2022
Q3 		$0 Buy
+5
New +$7 ﹤0.01% 907

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1832 Asset Management's LCTX Position: Q1 2023 in Review

1832 Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2023, closing a stake of 5 shares — an estimated $5 sold.

1832 Asset Management first reported a position in LCTX in Q3 2022 and held it in 2 quarters. The position peaked at $5 in Q4 2022. 115 funds tracked by Wall St. Rank hold LCTX as of Q1 2023.

  • 1832 Asset Management reported no remaining Lineage Cell Therapeutics position as of Q1 2023 after selling out during the quarter.
  • 1832 Asset Management sold 5 Lineage Cell Therapeutics shares in Q1 2023, an estimated $5.
  • 1832 Asset Management first reported a position in Lineage Cell Therapeutics in Q3 2022 and held it in 2 quarters.
  • 1832 Asset Management's Lineage Cell Therapeutics position peaked at $5 in Q4 2022.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2023.

Based on 1832 Asset Management's 13F filing for Q1 2023, filed 12 May 2023.